Literature DB >> 7539469

Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus.

M Amagai1, T Hashimoto, K J Green, N Shimizu, T Nishikawa.   

Abstract

Patients with the autoimmune blistering disease pemphigus foliaceus (PF) have circulating autoantibodies directed against the desmosomal cadherin desmoglein 1 (Dsg1). Based on the fact that purified IgG fractions from PF patients induce loss of cell adhesion in organ culture and in a neonatal mouse model, it has been proposed that these anti-Dsg1 antibodies play a pathogenic role in blister formation. To directly address whether antibodies in PF sera specific for the Dsg1 extracellular domain are indeed pathogenic in the disease, PFIg, a chimeric protein containing the entire extracellular domain of human Dsg1 and the constant region of human IgG1, was produced by baculovirus expression. Incubation of PF patients' sera with the PFIg baculoprotein removed the immunoreactivity of autoantibodies against keratinocyte cell surfaces in all 20 PF and eight Brazilian PF patients' sera tested. This adsorption was conformation dependent, because PFIg protein denatured by low pH or heat was no longer able to adsorb the immunoreactivity of PF sera. Furthermore, the incubation with the PFIg baculoprotein eliminated the pathogenic activity of PF patients' sera and prevented gross blister formation in a neonatal mouse model of pemphigus. Anti-Dsg1 antibodies eluted from the PFIg protein column were pathogenic as they resulted in the appearance of gross blisters in neonatal mice with typical histologic findings of PF. These observations indicate that the extracellular domain of Dsg1 expressed by baculovirus is capable of specifically immunoadsorbing pathogenic autoantibodies from PF patients' sera and provide direct evidence that the anti-Dsg1 autoantibodies in PF sera are indeed pathogenic. The availability of this Dsg1 recombinant protein may facilitate the development of antigen-specific plasmapheresis as a novel therapeutic strategy in pemphigus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539469     DOI: 10.1111/1523-1747.ep12606168

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  37 in total

1.  Pemphigus vulgaris: the other half of the story.

Authors:  R S Kalish
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy.

Authors:  John R Stanley; Ken Ishii; Don L Siegel; Aimee S Payne
Journal:  Vet Dermatol       Date:  2009-10       Impact factor: 1.589

4.  [Transformation of pemphigus foliaceus into pemphigus vulgaris].

Authors:  C Mühlhoff; M Megahed
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

Review 5.  Complement and cutaneous autoimmune blistering diseases.

Authors:  Elizabeth Lessey; Ning Li; Luis Diaz; Zhi Liu
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis.

Authors:  J Wang; J Kwon; X Ding; J A Fairley; D T Woodley; L S Chan
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

7.  Enrichment of total serum IgG4 in patients with pemphigus.

Authors:  T Funakoshi; L Lunardon; C T Ellebrecht; A R Nagler; C E O'Leary; A S Payne
Journal:  Br J Dermatol       Date:  2012-09-27       Impact factor: 9.302

8.  Desmoglein-1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem).

Authors:  M S Lin; C L Fu; V Aoki; G Hans-Filho; E A Rivitti; J R Moraes; M E Moraes; A M Lazaro; G J Giudice; P Stastny; L A Diaz
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

9.  Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.

Authors:  M Amagai; T Nishikawa; H C Nousari; G J Anhalt; T Hashimoto
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Evaluation of recombinant antigen-based assays for diagnosis of bullous autoimmune diseases.

Authors:  G D'Agosto; A Latini; M Carducci; A Mastroianni; A Vento; P Cordiali Fei
Journal:  Clin Diagn Lab Immunol       Date:  2004-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.